Zevra Therapeutics Inc. (ZVRA)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Zevra Therapeutics Inc. (ZVRA) is up 41.2% since the beginning of the year. At $13 per share, ZVRA is trading 11.4% below its 52-week high of $14. Investors who bought $1,000 worth of ZVRA shares 5 years ago would now be looking at an investment worth $885.

Zevra Therapeutics Inc. (ZVRA) has returned 41.18% so far this year and 39.93% over the past 12 months. Over the last ten years, ZVRA has returned -15.28% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.

Based on dividend-adjusted daily data since Apr 16, 2015, ZVRA's average daily return is +0.04%, while the average monthly return is +0.57%. At this rate, an investment would double in approximately 10.2 years.

Historically, 49% of months were positive and 51% were negative. The best month was Nov 2020 with a return of +77.2%, while the worst month was May 2016 at -57.2%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 9 months.

On a daily basis, ZVRA closed higher 46% of trading days. The best single day was Mar 3, 2021 with a return of +42.8%, while the worst single day was May 6, 2016 at -55.9%.

Zevra Therapeutics Inc. has an annualized alpha of -0.47%, beta of 0.84, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since April 16, 2015.

• This stock participated in 144.46% of S&P 500 Index downside but only 3.61% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ZVRA ranks 62 for risk / return — better than 62% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Zevra Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Zevra Therapeutics Inc. was 99.27%, occurring on May 22, 2020. The portfolio has not yet recovered.

The current Zevra Therapeutics Inc. drawdown is 96.65%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Zevra Therapeutics Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Zevra Therapeutics Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.